Glaukos Corporation (GKOS)

Market Cap	4.99B
Revenue (ttm)	314.71M
Net Income (ttm)	-134.66M
Shares Out	50.19M
EPS (ttm)	-2.78
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	277,837
Open	100.28
Previous Close	100.11
Day's Range	98.53 - 100.62
52-Week Range	45.38 - 103.66
Beta	1.10
Analysts	Strong Buy
Price Target	95.45 (-4.05%)
Earnings Date	May 1, 2024

About GKOS

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR,...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jun 25, 2015
• Employees: 907
• Stock Exchange: NYSE
• Ticker Symbol: GKOS

Financial Performance

In 2023, Glaukos's revenue was $314.71 million, an increase of 11.26% compared to the previous year's $282.86 million. Losses were -$134.66 million, 35.8% more than in 2022.

Analyst Forecast

According to 11 analysts, the average rating for GKOS stock is "Strong Buy." The 12-month stock price forecast is $95.45, which is a decrease of -4.05% from the latest price.

Price Target

$95.45

(-4.05% downside)

Analyst Consensus: Strong Buy